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Factors associated with dyslipidemia in Chinese patients with uncomplicated 
hypertension were investigated in 1,139 patients newly prescribed a single 
antihypertensive drug in the public primary healthcare setting in Hong Kong, where 
their fasting lipid profiles were measured 4 to 16 weeks after the first prescription. 
Multivariate logistic regression showed that thiazide users were more likely (OR 3.67, 
95% C.I. 1.13, 11.88, p=0.030) to have adverse (> 6.2mmol/l) total cholesterol (TC) 
compared with drugs acting on the renin angiotensin system (RAS), but the absolute 
difference in mean TC between thiazide users and all patients was small ( 0.14 mmol/l), 
while advanced age and male gender were also associated with some aspects of 
dyslipidemia.  Clinicians should be aware of the increased risk of dyslipidemia in these 
groups, but the mild dyslipidemic profile associated with thiazides should not in itself 
deter its use as a possible first-line antihypertensive agent among Chinese patients.  
 
Dyslipidemia has been recognized as a strong predictor of cardiovascular disease1.  There is 
increasing evidence that dyslipidemia is associated with2 and possibly a causative factor in 
hypertension3.  Studies on the potential predictive factors of dyslipidemia among established 
hypertensive patients are few, and evidence on the possible relationship between 
antihypertensive drug classes and dyslipidemia is mixed4,5.  To our knowledge there are few 
reports on the risk factors of dyslipidemia among hypertensive patients of Chinese ethnicity.  
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This study examined the lipid profiles of Chinese hypertensive patients newly prescribed a 
single antihypertensive agent and evaluated the risk association between potential predictive 
factors and the occurrence of dyslipidemia. 
 
We retrieved data from the clinical database of the Hospital Authority, Hong Kong which 
consists of patient demographics, clinical diagnoses, prescription details and laboratory 
investigation results in every out-patient consultation.  Previous evaluations of this clinical 
tool for research purposes6 found a high level of data completeness with respect to 
demographic data (100%) and prescription details (99.98%) (unpublished data).  The present 
study included Chinese individuals residing in one large cluster which has an approximate 
population of 1.3 million.  This cluster is further divided into 3 separate regions, namely 
Shatin, Tai-Po and the North district, from the most affluent to the least.  Patients attending 
public primary care clinics for the first time who were coded by physicians with International 
Classification of Primary Care K86 [uncomplicated hypertension] and were newly prescribed 
an antihypertensive agent during the study period of January 2004 to June 2007, were 
included.  In addition, eligible patients must have had fasting lipid profiles measured 4 to 16 
weeks after prescription.  Exclusion criteria included patients with: concomitant 
cardiovascular risks; clinical conditions which could confound the prescription choice of 
antihypertensive drugs (supplemental file 1); discontinuation or changes to their drug 
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prescription before lipid profile was measured; or prescribed at least one lipid modifying 
agent during the study period.  The proportions of patients with desirable, borderline and 
adverse levels of lipid profiles were studied for TC (<5.2; 5.2-6.1; >6.2 mmol/l), TG (<1.7; 
1.7-2.2; > 2.3 mmol/l), LDL-C (<2.6; 2.6-4.0; > 4.1 mmol/l) and HDL-C (> 1.5; 1.0-1.5; <1.0 
mmol/l) by each major drug class.  Lipid profiles were measured after an overnight fast of 8 
to 12 hours.  LDL-C was calculated using the Friedewald formula  but direct LDL-C was 
measured instead where TG level was 
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> 4.5 mmol/L.  Student’s t-tests were used for 
comparison of continuous variables while chi-square tests were used for categorical variables.  
Separate unconditional binary logistic regression analyses for each lipid parameter (TC [Total 
Cholesterol], Triglyceride [TG], Low Density Lipoprotein-Cholesterol [LDL-C] and High 
Density Lipoprotein-Cholesterol [HDL-C]) were conducted.  Independent predictors and 
covariates included patient age, gender, patient’s payment status (fee-waivers vs. payers), 
district of residence, types of clinics attended (general vs. family medicine specialist vs. staff 
clinics) and the antihypertensive drug classes prescribed (thiazide diuretics, β-blockers, 
calcium channel blockers [CCB] and RAS-modifiers).  
 
There were 1,139 eligible patients with a mean age of 61 years, 59.3% of which were females 
in the sample (supplemental file 2).  Among the four drug classes, thiazide users had the 
highest mean values of TC (5.38 mmol/l) and TG (1.59 mmol/l), CCB users had highest 
 4
levels of LDL-C (3.22 mmol/l) and BB users had the lowest levels of HDL-C (1.52 mmol/l).  
These apparent differences in lipid parameters between drug groups were statistically 
insignificant (p=0.265 to 0.881).  For all lipid parameters, the crude differences in proportion 
of patients with adverse lipid profiles amongst the various drug classes did not reach 
statistical significance either (p=0.213 to 0.951) (supplemental file 3).  From multivariate 
regression analyses, thiazide users were 3.67 times more likely than RAS to show adverse TC 
levels (OR 3.670, 95% C.I. 1.134, 11.876, p=0.030) (Table 1).  However, the absolute 
difference between mean TC between thiazide users and all patients was only 0.14 mmol/l.  
When compared with younger age groups, advanced age (>50 years) was found to be 
positively associated with borderline high TC (OR 1.513 to 1.788, p=0.015 to 0.057) and high 
TC (OR 2.493 to 2.834, p=0.002 to 0.016) but negatively associated with HDL-C (OR 0.523 
to 0.626, p=0.013 to 0.042) (Table 1). Male patients were also more likely to have less than 
optimal HDL-C (OR 2.535, p<0.001). 
 
Thiazide diuretics have been shown to increase levels of TC and LDL-C by 5% to 7% 
without alteration of HDL-C in the first year of antihypertensive treatment8, while other 
studies reported a decline in lipid profiles with use of diuretics9.  Our finding that thiazides 
are positively associated with adverse TC levels implies association with 
hypercholesterolemia in Chinese hypertensive patients, noting that the absolute increase in 
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TC levels was relatively mild and comparable to Kasiske et al’s study10 which reported a 
similar difference in mean TC (0.12 mmol/l) between thiazide users and other 
antihypertensive drug classes.   
 
Published studies on the association of age and gender with dyslipidemia are inconclusive.  
Increased serum cholesterol was found with increasing age by Kesteloot et al11.  Cai et al12 
reported a rise in HDL-C with age in men only and with decreasing concentrations in women 
after age 50.  In this study both age and gender were associated with dyslipidemia which 
may represent a new finding among ethnic Chinese.   
 
Some limitations of this study should be mentioned.  First, the lack of baseline lipid profiles 
which could act as reference values prevents before-after exposure comparisons of lipid 
levels.  Also, we recognize the absence of ICPC coding which more accurately excludes the 
presence of relevant co-morbidities.  Secondly, this study cannot prove causative 
relationships between predictor variables and lipid profiles, which can only be addressed 
through a prospective cohort design.   
 
In conclusion, in the present study on Chinese subjects, thiazide use was associated with 
elevated cholesterol levels, but the absolute increase in TC was small. Increasing age and 
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male gender were also associated with increased risk of dyslipidemia. Clinicians should be 
aware of these increased risks, but the mild dyslipidemic profile associated with thiazides 
should not in itself deter its use as a possible first-line antihypertensive agent among Chinese 
patients.  
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Table 1  Independent associated factors of dyslipidemia with above borderline and adverse readings a
Total Cholesterol 
Above borderline            Adverse 
Triglycerides 
Above borderline        
 
LDL-Cholesterol 
Above borderline             Adverse 
HDL-Cholesterol b
Less than optimal     
 
OR (95% CI) p OR (95% CI) p 
 
OR (95% CI) 
 
p       OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age (years)
<50 
50-59 
60-69 
>70 
 
1.0  (ref) 
1.513 (0.988, 2.318) 
1.788 (1.120, 2.854) 
1.763 (1.081, 2.876) 
 
 
0.057 
0.015 
0.023 
 
1.0  (ref) 
2.834 (1.445, 5.557) 
2.493 (1.185, 5.245) 
2.808 (1.327, 5.942) 
 
 
0.002 
0.016 
0.007 
 
1.0  (ref) 
1.413 (0.880, 2.269) 
1.313 (0.776, 2.224) 
1.195 (0.696, 2.052) 
 
 
0.152 
0.310 
0.519 
 
1.0  (ref) 
1.008 (0.547, 1.855) 
1.630(0.796, 3.336) 
0.902 (0.449, 1.812) 
 
 
0.981 
0.181 
0.773 
 
1.0  (ref) 
2.733 (1.003, 7.452) 
1.791 (0.547, 5.867) 
1.867 (0.602, 5.789) 
 
 
0.049 
0.336 
0.280 
 
1.0  (ref) 
0.626 (0.399, 0.984) 
0.592 (0.362, 0.966) 
0.523 (0.315, 0.870) 
 
 
0.042 
0.036 
0.013 
Gender 
Female 
Male 
 
1.0  (ref) 
1.004 (0.723, 1.394) 
 
 
0.981 
 
1.0  (ref) 
0.755 (0.467, 1.220) 
 
 
0.755 
 
1.0  (ref) 
1.282 (0.900, 1.827) 
 
 
0.169 
 
1.0  (ref) 
1.147 (0.706, 1.863) 
 
 
0.579 
 
1.0  (ref) 
1.176 (0.569, 2.430) 
 
 
0.662 
 
1.0  (ref) 
2.535 (1.778, 3.615) 
 
 
<0.001 
Payment 
status 
Fee-waivers 
Fee-payers 
 
 
1.0 (ref) 
0.863 (0.608, 1.225) 
 
 
 
0.410 
 
 
1.0 (ref) 
0.777 (0.477, 1.267) 
 
 
 
0.312 
 
 
1.0 (ref) 
0.993 (0.681, 1.448) 
 
 
 
0.972 
 
 
1.0 (ref) 
0.732 (0.435, 1.230) 
 
 
 
0.239 
 
 
1.0 (ref) 
0.865 (0.394, 1.896) 
 
 
 
0.717 
 
 
1.0 (ref) 
1.122 (0.783, 1.607) 
 
 
 
0.531 
District of 
residence 
Shatin 
Taipo 
North 
Others 
 
 
1.0 (ref) 
0.630 (0.344, 1.153) 
1.052 (0.672, 1.647) 
1.182 (0.571, 2.446) 
 
 
 
0.134 
0.825 
0.653 
 
 
1.0 (ref) 
0.257 (0.096, 0.685) 
0.652 (0.361, 1.175) 
0.916 (0.351, 2.386) 
 
 
 
0.007 
0.155 
0.857 
 
 
1.0 (ref) 
0.762 (0.388, 1.497) 
0.876 (0.537, 1.431) 
0.783 (0.365, 1.679) 
 
 
 
0.430 
0.597 
0.529 
 
 
1.0  (ref) 
0.265 (0.105, 0.670) 
0.755 (0.350, 1.628) 
1.015 (0.313, 3.296) 
 
 
 
0.005 
0.474 
0.980 
 
 
1.0  (ref) 
0.183 (0.050, 0.674) 
0.437 (0.165, 1.160) 
0.621 (0.121, 3.193) 
 
 
 
0.011 
0.096 
0.569 
 
 
1.0  (ref) 
1.228 (0.631, 2.387) 
0.880 (0.544, 1.422) 
1.014 (0.454, 2.265) 
 
 
 
0.545 
0.602 
0.973 
Service type 
General  
FMSC 
Staff clinic  
 
1.0 (ref) 
2.205 (1.050, 4.630) 
1.638 (0.690, 3.886) 
 
 
0.037 
0.263 
 
1.0 (ref) 
2.669 (1.053, 6.763) 
1.037 (0.278, 3.868) 
 
 
0.039 
0.957 
 
1.0 (ref) 
0.868 (0.404, 1.863) 
0.598 (0.231, 1.547) 
 
 
0.716 
0.289 
 
1.0  (ref) 
0.858 (0.257, 2.867) 
0.637 (0.169, 2.399) 
 
 
0.803 
0.505 
 
1.0  (ref) 
0.962 (1.195, 4.734) 
1.466 (0.244, 8.797) 
 
 
0.962 
0.676 
 
1.0  (ref) 
1.167 (0.511, 2.663) 
0.801 (0.318, 2.019) 
 
 
0.715 
0.639 
Drug class 
RAS 
β-blockers 
Thiazide 
CCB 
 
1.0 (ref) 
1.048 (0.550, 2.000) 
1.437 (0.730, 2.825) 
1.317 (0.691, 2.508) 
 
 
0.886 
0.294 
0.402 
 
1.0 (ref) 
2.293 (0.726, 7.242) 
3.670 (1.134, 11.876) 
2.769 (0.870, 8.811) 
 
 
0.157 
0.030 
0.085 
 
1.0 (ref) 
1.132 (0.554, 2.311) 
1.204 (0.575, 2.522) 
1.102 (0.538, 2.255) 
 
 
0.734 
0.622 
0.790 
 
1.0  (ref) 
0.649 (0.241, 1.746) 
0.802 (0.289, 2.225) 
0.625 (0.233, 1.681) 
 
 
0.392 
0.671 
0.352 
 
1.0  (ref) 
1.622 (0.337, 7.799) 
0.954 (0.181, 5.036) 
1.535 (0.315, 7.477) 
 
 
0.546 
0.956 
0.596 
 
1.0  (ref) 
0.914 (0.454, 1.843) 
0.783 (0.380, 1.616) 
0.677 (0.335, 1.369) 
 
 
0.802 
0.508 
0.277 
(HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; FMSC: Family Medicine Specialist Clinics; CCB: Calcium Channel Blockers; RAS: drugs acting on the rennin 
angiotensin system.  a: Above borderline lipid profiles were defined as, respectively, TC > 5.2 mmol/l; TG > 1.7 mmol/l; LDL-C > 2.6 mmol/l; less than optimal for HDL-C defined as < 
1.6 mmol/l; Adverse results were defined as TC > 6.2 mmol/l; TG > 2.3 mmol/l; LDL-C > 4.1 mmol/l; HDL-C < 1.0 mmol/l.  b: None of the patients had adverse HDL-Cholesterol 
readings.  All adjusted Odds Ratios (OR) were adjusted for age, gender, payment status, district of residence, service types of attended clinics and drug classes as listed in table) 
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Table 2 Summary Table 
What is known about topic 
z Hypertension and dyslipidemia often coexist and there is increasing evidence that one 
may lead to the occurrence of another. 
z There were few studies on the factors associated with dyslipidemia among patients with 
uncomplicated hypertension, especially in ethnic Chinese patients 
z Evidence on the association of antihypertensive drug classes with dyslipidemia is 
presently mixed. 
What this study adds 
z Advanced age, male gender and use of thiazide were associated with higher risk of some 
aspects of dyslipidemia in hypertensive patients prescribed a single antihypertensive 
drug. 
z Thiazide use was associated with hypercholesterolemia yet the absolute increase in total 
cholesterol was small  
z Chinese patients with uncomplicated hypertension newly prescribed a single 
antihypertensive agent with these associated factors should have more meticulous 
screening of their lipid profiles.  
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